Lv5
1156 积分 2024-04-01 加入
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
6天前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
7天前
已完结
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
7天前
已完结
Dosimetric advantages of a novel X-Ray/γ-Ray integrated radiotherapy platform in cervical carcinoma: A comparative treatment planning study
9天前
已完结
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
10天前
已完结
Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079)
10天前
已完结
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix
13天前
已完结
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
14天前
已完结
Molecular and immune correlates of response to first-line de-escalated chemotherapy plus penpulimab and anlotinib in advanced cervical cancer
19天前
已完结
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
24天前
已完结
皖公网安备34019202002308
